Sensitivity or
Quinine was the first established antimalarial drug, and it has been used to treat malaria for centuries (26) . Intravenous quinine is the standard therapy for severe Plasmodium falciparum malaria in Africa and many other areas, although intravenous artesunate recently showed superior efficacy in Asia (15) . Quinine is also a second-line regimen used for the treatment of uncomplicated malaria in many countries after failure of initial therapy. Recent WHO guidelines suggest second-line use of quinine in combination with an antibiotic (55) , but monotherapy is still commonly used (59) . In addition, with failures of older therapies and limited availability of new artemisinin-based combination therapies, quinine is increasingly used as a first-line drug for treatment of uncomplicated malaria in Africa (1) .
The use of quinine to treat uncomplicated malaria is problematic for a number of reasons. First, the efficacy of quinine for the treatment of uncomplicated malaria is uncertain. A number of studies and case reports have demonstrated apparent failures after quinine therapy for falciparum malaria in Asia (9, 41) , South America (46, 60) , and Africa (22, 31, 38) . Recent studies incorporating detailed assessments of treatment efficacy or effectiveness have shown 28-day failure rates of Ͼ10% after 7-day courses of quinine for uncomplicated malaria in Sudan (3), Thailand (40) , and Uganda (1) . In Uganda, the 28-day genotype-corrected failure rate was 23%; some failures may have been due to poor treatment compliance, but no association between measures of compliance and treatment efficacy was identified (1) . On the other hand, some studies have shown excellent efficacy for quinine, including over 95% success after 14 to 28 days for the treatment of falciparum malaria in Equatorial Guinea (45) , in Venezuela (2) , and in returned travelers in France (32) . Second, quinine is poorly tolerated, especially later in the course of 7 days of treatment, suggesting that noncompliance with full treatment courses is common (19, 50) . Noncompliance may limit treatment efficacy and help to select for drug-resistant parasites. Third, widespread quinine use engenders risks of serious toxicities, including cardiac effects, hypoglycemia, hemolysis, and thrombocytopenia (50) . Fourth, quinine pharmacokinetics are variable, and metabolism can be altered by coadministration of a number of other drugs (42) .
Diminished in vitro responsiveness of P. falciparum to quinine has been documented in parasites from Asia, South America, and Africa (57) . Available studies have suggested that parasites from Africa generally remain sensitive to quinine (4, 21, 24, 37, 43, 51) , but methodologies have varied, and strict cutoffs for in vitro drug resistance have not been established. Despite relatively low 50% inhibitory concentrations (IC 50 s), it is noteworthy that absolute sensitivities of African P. falciparum strains have varied greatly. For example, in a recent study in Uganda, the IC 50 s for quinine against freshly isolated parasites varied about 50-fold (29) .
Mediators of P. falciparum resistance to quinine are poorly understood (58) . The resistance phenotype is consistent with a complex genetic basis, as changes in sensitivity have appeared to evolve gradually. Quantitative trait locus analysis identified three genes predicted to play roles in the responsiveness of P. falciparum to quinine (18) : pfcrt, which encodes a predicted transporter in which the 76T mutation is the principal mediator of resistance to chloroquine (12, 49) ; pfmdr1, which encodes a P-glycoprotein homolog for which different polymorphisms are associated with altered responses to a number of antimalarials (34, 44, 52) ; and pfnhe1, which encodes a putative sodium-hydrogen exchanger (18) . Among known variations, an increased copy number of pfmdr1 is most clearly associated with the response to quinine, with its amplification being associated with 2-to 3-fold decreases in sensitivity (33, 47, 58) . Increased pfmdr1 copy number has been very uncommon in Africa, although it has recently been reported in West Africa (56) . Single nucleotide polymorphisms (SNPs) in pfcrt and pfmdr1 are also associated with alterations in quinine sensitivity (10, 27, 44, 49) . In Ugandan field isolates, the pfmdr1 1246Y mutation was associated with diminished sensitivity to quinine (29) . However, unlike analyses of chloroquine sensitivity, associations between quinine sensitivity and polymorphisms in pfcrt and pfmdr1 have been modest, suggesting important roles for additional polymorphisms, including pfnhe1 and other loci (18) .
Considering variation in pfnhe1, reducing its expression by about 50% using allelic exchange led to a 30% increase in quinine sensitivity in some but not other parasite strains (28) . Four studies have recently evaluated associations between polymorphisms at pfnhe1 microsatellite 4760 (ms4760) and in vitro sensitivity of parasites from individuals infected in countries where malaria is endemic. In 23 culture-adapted strains from multiple countries (20) and 60 freshly isolated strains from the China-Myanmar border (25) , increased numbers of the DNNND repeat were associated with decreased quinine sensitivity, while increased numbers of the DDNHNDN HNND repeat within the same microsatellite were associated with increased quinine sensitivity (20) . In 29 fresh isolates from the Kenyan coast, 2 DNNND repeats were associated with decreased sensitivity to quinine compared to the sensitivities of isolates with 1 or 3 copies, and there was no association between the number of DDNHNDNHNND repeats and quinine susceptibility (30) . In 83 freshly isolated strains from individuals infected in Africa, multiple polymorphisms were seen in ms4760, but, in contrast to the above reports, significant associations were not seen between the numbers of the DNNND repeat and quinine sensitivity, and increased copies of the DDNHNDNHNND repeat were associated with decreased quinine sensitivity (5) . Taken together, recent results suggest an uncertain role for pfnhe polymorphisms in quinine sensitivity.
To further characterize associations between polymorphisms in pfcrt, pfmdr1, and pfnhe1 and sensitivity to quinine, we evaluated key sequences in P. falciparum parasites from two studies in Kampala, Uganda. The first study provided access to a large number of clinical isolates for which in vitro sensitivity to quinine was determined (29) . The second study provided samples from a recent assessment of the clinical effectiveness of quinine for the treatment of uncomplicated malaria (1). Our results are consistent with the conclusion that quinine responsiveness is a complex trait, with polymorphisms in multiple genes contributing to drug sensitivity. (11, 17) . In this trial, patients were offered all medical care through the study clinic, so use of antimalarial drugs outside the study protocol was uncommon. Children were treated with quinine only for complicated malaria or after failure of a combination regimen, both uncommon events (17) . Samples were collected for parasite culture between August 2006 and May 2008. The second trial was a randomized comparison of quinine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in children aged 6 to 59 months (1); 86 children were enrolled into the quinine treatment arm of the study. Responses over 28 days were graded on the basis of standard WHO criteria, with genotyping used to distinguish recurrences due to reinfection from those due to recrudescence (1). In both trials, when falciparum malaria was diagnosed on the basis of fever or a history of fever and parasites on Giemsa-stained blood smears, blood spots were collected on filter paper (Whatman 3MM) for subsequent molecular studies. All study subjects provided written informed consent. Both trials and the analysis of cultured parasites were approved by the Uganda National Council for Science and Technology, the Makerere University Research and Ethics Committee, and the University of California, San Francisco, Committee on Human Research.
MATERIALS AND METHODS

Clinical
Parasite culture and measurement of in vitro quinine sensitivity. For the first trial described above, at the time of diagnosis of an episode of malaria and before the initiation of therapy, blood was collected in heparinized tubes and transported within 30 min to our laboratory. Giemsa-stained thin blood smears were examined, and if P. falciparum monoinfection was confirmed, culture was initiated. Blood was centrifuged, plasma and buffy coat were removed, and the erythrocyte pellet was washed twice with RPMI 1640 medium at 37°C. Parasites were diluted with 2% group O uninfected erythrocytes to obtain a density of 0.05%. Aliquots (200 l) were then cultured in 10 ml RPMI 1640 medium supplemented with 25 mM HEPES, 0.2% NaHCO 3 , 0.1 mM hypoxanthine, 100 g/ml gentamicin, and 0.5% Albumax II serum substitute to produce a packed cell volume of ϳ2%. Sensitivities were measured for multiple drugs, including quinine, as previously described utilizing 96-well culture plates predosed with serial dilutions of drugs and a histidine-rich protein 2 (HRP-2)-based enzymelinked immunosorbent assay (ELISA) (29) . For this assay, optical density values were fitted to normal curves based on serial dilutions of HRP-2 standards, and IC 50 s were calculated on the basis of a nonlinear regression model.
Analysis of parasite genetic polymorphisms. DNA was extracted from filter paper samples by extraction with Chelex, as previously described (35) . We screened for polymorphisms at pfcrt K76T and pfmdr1 N86Y, Y184F, S1034C, N1042D, and D1246Y by PCR amplification of flanking sequences, sequencespecific restriction enzyme digestion, and evaluation of the digested fragments by agarose gel electrophoresis, all as previously reported (12, 16) . Estimates of pfmdr1 gene copy number were carried out by quantitative PCR as previously reported (14, 39) , using a 7500 real-time PCR system (Applied Biosystems).
The ms4760 locus of the pfnhe1 gene was amplified with primers NHE-A (5Ј-AGTCGAAGGCGAATCAGATG-3Ј) and NHE-B (5Ј-GATACTTACGAA CATGTTCATG-3Ј) (53), using a Titanium PCR kit (Clontech). Each 20-l PCR mixture included 14.8 l H 2 O, 2 l 10ϫ buffer, 0.4 l deoxynucleoside triphosphate mix (10 mM each), 0.2 l of each 20 M primer, 0.4 l 50ϫ Titanium Taq, and 2 l of target DNA template. A touchdown PCR approach (23) used the following parameters: 94°C for 120 s; 10 cycles of 94°C for 15 s, 63°C for 30 s, and 68°C for 90 s; 25 cycles of 94°C for 15 s, 58°C for 30 s, and 68°C for 90 s; and 1 cycle of 68°C for 7 min. The PCRs were performed on a Bio-Rad C1000 or S1000 thermocycler. PCR products were purified using ExoSAP-IT (USB). About 150 ng of each purified DNA was sequenced using 15 pmol primers NHE-C (5Ј-A TCCCTGTTGATATATCGAATG-3Ј) and NHE-D (5Ј-TTGTCATTAGTACC CTTAGTTG-3Ј) (53) at the University of California, San Francisco, Genomics Core Facility using ABI BigDye (version 3.1) Terminator sequencing chemistry and an ABI Prism 3730xl capillary DNA analyzer (Applied Biosystems).
For analysis of pfnhe1 ms4760, nucleotide traces were physically inspected using the SeqMan tool (DNAStar Lasergene 8 software). The sequences were then translated using the Edit Sequence tool and aligned using the MEGALIGN program (DNAStar). Microsatellite 4760 profiles that were not among the 35 previously reported profiles (5, 18, 25, 53) , were confirmed by repeat template amplification and sequencing.
Statistical analysis. Quinine IC 50 s were calculated using a polynomial regression model and HN-NonLin software (http://malaria.farch.net) and were considered continuous variables. Differences in quinine IC 50 s were examined using the Mann-Whitney U test for comparisons of two groups or the Kruskal-Wallis test with Dunn's multiple-comparison posttest for comparisons of more than two groups. Infections with mixed mutant/wild-type genotypes at the pfcrt and pfmdr1 loci were analyzed as mutant, in view of the expected phenotype of the infection. Associations between alleles and treatment outcomes were assessed using Fisher's exact two-tailed test. Tests were carried out using GraphPad Prism software. In all cases the statistical significance level was set at a P value of Ͻ0.05.
Nucleotide sequence accession numbers. Nucleotide sequences for the Ugandan isolates were deposited in the GenBank database under accession numbers HQ412347 to HQ412386.
RESULTS
Samples available for study. We evaluated polymorphisms in two sets of samples from patients infected with P. falciparum in Kampala. First, we evaluated samples from a cohort of children who were followed in a drug efficacy trial comparing three combination regimens for uncomplicated falciparum malaria (17) . Blood samples collected upon presentation with uncomplicated falciparum malaria and before the initiation of therapy were used to inoculate cultures, and in vitro sensitivities to quinine were determined immediately after sample collection (29) . Second, we evaluated 79 samples from the quinine treatment arm of a trial with children randomized to treatment of uncomplicated falciparum malaria with either artemetherlumefantrine or quinine (1). Patients were followed over 28 days after presentation, and treatment outcomes were classified on the basis of WHO criteria (54) ; in vitro sensitivities were not assessed for samples from this trial.
Associations between polymorphisms and in vitro quinine sensitivity. The in vitro sensitivities to quinine of isolates collected in Kampala varied widely, with a geometric mean IC 50 of 94.4 nM and an IC 50 range of from 15 to 761 nM (29) . We first assessed known polymorphisms in pfcrt and pfmdr1 and searched for associations with the sensitivity of cultured parasites to quinine. The pfcrt 76T mutation was seen in all except 1 of 169 tested samples. Thus, many parasites were highly sensitive to quinine, despite the presence of pfcrt 76T, and it was not possible to assess the role of this polymorphism in quinine sensitivity. For pfmdr1, the N86Y and 1246Y mutations were also very common, although they were not fixed; the 184F mutation was less common; and mutations at positions 1034 and 1042, which have principally been described in samples from regions other than Africa, were not seen (Table 1) . For the 86Y, 184F, and 1246Y polymorphisms, mutant parasites had diminished sensitivity to quinine (Table 1) , but none of these differences attained statistical significance. Considering combinations of polymorphisms, there was a trend toward decreased quinine sensitivity with increased numbers of mutations ( Table 2 ). The difference was statistically significant, after adjustment for multiple comparisons, between isolates having any 1 of the pfmdr1 mutations and isolates having all 3 pfmdr1 mutations (P ϭ 0.02). Increased copy number of pfmdr1 has been associated with diminished quinine sensitivity in Asia but has been seen uncommonly in African isolates. To consider a potential contribution of pfmdr1 copy number on results from Uganda, we analyzed 58 samples with a range of quinine sensitivities (26 samples with IC 50 s of from 15 to 22 nM, 10 with IC 50 s of from 41 to 298 nM, 22 with IC 50 s of from 308 to 755 nM). All of these parasites contained only a single copy of the pfmdr1 gene.
We next evaluated associations between polymorphisms in pfnhe1 ms4760 and quinine sensitivity. We sequenced 240 isolates, and in vitro quinine sensitivity data were obtained for 172 isolates. We found a high degree of polymorphism at this locus. We found 46% (16/35) of the previously described ms4760 haplotypes. In addition, we identified 24 previously undescribed ms4760 haplotypes, now designated ms4760-36 to ms4760-59 (Table 3 and Fig. 1 ). Nucleotide sequences for the Ugandan isolates were deposited in the GenBank database under the accession numbers indicated category, but parasites with 2 copies of either repeat were somewhat less sensitive to quinine than those with 1 or 3 or more repeats (Table 4) , although the associations between repeat number and quinine IC 50 were not significant (P ϭ 0.20 and 0.15 for DNNND and DDNHNDHNND, respectively). Considered together, the impacts of known polymorphisms in pfcrt, pfmdr1, and pfnhe1 did not lead to identification of significant associations. Considering the combinations leading to the least and the most sensitive parasites, those with the wildtype sequence at pfmdr1 positions 86 and 1246 and 3 DNNND repeats were more sensitive to quinine (IC 50 , 55 nM) than parasites with mutant pfmdr1 sequences and 2 DNNND repeats (IC 50 , 151 nM), but the differences were not statistically significant (P ϭ 0.13; Table 5 ).
Associations between polymorphisms and quinine treatment responses. Of 79 samples available from the quinine treatment arm of a recent drug effectiveness trial in Kampala (1), we excluded 12 samples from patients classified by genotyping as clinical failures due to new infection during follow-up and 1 due to failed amplification, leaving 66 samples for analysis, including 46 (70%) from patients who experienced adequate clinical and parasitological responses and 20 (30%) from treatment failures due to recrudescent parasites (2 early treatment failures, 11 late clinical failures, and 7 late parasitological failures). All evaluable isolates (2 failed to amplify) had the pfcrt 76T mutation. For pfmdr1, the prevalence rates of the 86Y, 184F, and 1246Y mutations were very similar between (53) . The DNNND repeats are in block II, and the DDNNNDNHNDD repeats are in block V. Profiles ms4760-1 to ms4760-35 have been described previously (5, 18, 25, 53) ; ms4760-36 to ms4760-59 are described in this study. Profiles 4, 10, 11, 13, 14, 16, 17, 19, 20, 22, 25, 26, 28, 29, 30, 31, 32, 33 , and 34 were not observed in the present study. Other differences among sequences are indicated in boldface. Gaps were created for optimal alignment. isolates that led to adequate response or treatment failure (Fig. 2) . Combinations of any 2 or 3 pfmdr1 mutations were also not associated with treatment response. As with isolates collected for in vitro analyses, mutations at codons 1034 and 1042 (tested in all 66 isolates) or increases in copy number (tested in 55 samples) of pfmdr1 were not seen in any of the clinical isolates. We next considered the impact of polymorphisms in pfnhe1 on treatment responses. The numbers of DNNND and DDN HNDHNND repeats varied somewhat between groups, but there was no significant association between the number of repeats and clinical response (Fig. 3) . In particular, there was no significant difference in quinine treatment response between individuals harboring parasites with one versus two or more DNNND or DDNHNDNHNND repeats.
DISCUSSION
Polymorphisms in three P. falciparum genes have been linked to varied responses of malaria parasites to quinine. We considered associations between these polymorphisms and in vitro quinine sensitivity in samples from children with uncomplicated malaria in Uganda. We found modest associations between known polymorphisms in pfmdr1 and quinine sensitivity, including a significant decrease in sensitivity with an increased prevalence of combinations of the 86Y, 184F, and 1246Y mutations. Considering newly described polymorphisms in pfnhe1, we found a modest and statistically insignificant association between two copies and one or three or more copies of two adjacent repeats and decreased quinine sensitivity. We also assessed associations between P. falciparum polymorphisms and clinical outcomes using samples from a clinical trial of quinine for the treatment of uncomplicated malaria in Uganda. None of the tested polymorphisms was predictive of quinine treatment failure. Taken together, our results confirm prior findings showing modest associations between polymorphisms in pfmdr1 and quinine sensitivity, suggest that associations between pfnhe1 repeat numbers and quinine sensitivity are not as great as suggested in a recent paper (20) , and indicate that the known polymorphisms evaluated in the present study are unlikely to serve as reliable markers of quinine treatment outcomes.
Although quinine has retained good antimalarial efficacy in most areas, its clinical efficacy has decreased in some regions, especially in Asia (51) . Further, some reports have identified worrisome limitations in the efficacy of quinine in Africa, including our recent identification of a 23% failure rate for the treatment of uncomplicated falciparum malaria in Uganda (1). The recent Ugandan study did not include directly observed therapy, methodologies have varied among other studies, and the true incidence of quinine treatment failure in Africa is uncertain. Further, the relative contributions of different factors to treatment failure, including parasite resistance to quinine, poor compliance with therapeutic regimens, varied drug absorption and pharmacokinetics, and other factors, are unknown.
Of note, even in areas where quinine efficacy has appeared to remain good, such as sub-Saharan Africa, the sensitivity of individual P. falciparum isolates to the drug has varied widely. Nonetheless, the wide range in quinine sensitivity seen across Africa and recent evidence for quinine treatment failure in Africa suggest that the evolution of parasites with decreased drug sensitivity may be contributing to diminished clinical responses to the drug. The mediators of decreased quinine sensitivity of P. falciparum are uncertain. The well-described K76T polymorphism in the gene encoding the putative transporter pfcrt, which is the principal mediator of resistance to chloroquine (13, 49) , also appears to play a role in mediating quinine sensitivity, on the basis of the results of laboratory studies (49, 58) . The pfcrt 76T mutation was nearly universal in Ugandan isolates, so associations between this polymorphism and in vitro or clinical outcomes could not be studied. Polymorphisms in the gene encoding the multidrug resistance homolog pfmdr1 also play roles in resistance to multiple drugs (52, 58) . Amplification of pfmdr1 decreases sensitivity to quinine (39, 58) . The single nucleotide polymorphisms in pfmdr1 that are common in Africa, N86Y, Y184F, and D1246Y, have had less marked impacts on quinine sensitivity in laboratory studies (44, 48) . In evaluations of clinical isolates, associations between pfmdr1 polymorphisms and in vitro quinine sensitivity have been uncertain, but evaluations considering the common polymorphisms seen in Africa have been limited (6) . We recently evaluated pfmdr1 polymorphisms in the most and least sensitive of 196 isolates for which quinine sensitivity was measured in Uganda. The most resistant parasites were significantly more likely to harbor the pfmdr1 1246Y mutation, but not 86Y or 184F (29) . Considering overall results, parasites with any of the three pfmdr1 polymorphisms seen in our isolates were somewhat more resistant to quinine than those without the polymorphism (Table 1) , but the differences were not statistically significant. Considering the mutations together, an increasing number of mutations was associated with progressively greater quinine IC 50 s (Table 2) .
Recently, quantitative trait locus analysis identified variations in the pfnhe1 gene, in addition to pfcrt and pfmdr1, as potentially mediating quinine sensitivity (18) . Specifically, varied numbers of repeats in the ms4760 microsatellite were associated with quinine sensitivity. Following up on this report, four groups evaluated associations between ms4760 repeat numbers and in vitro quinine sensitivity. In 23 culture-adapted strains from multiple regions (20) and in 60 fresh isolates from the China-Myanmar border (25) , increasing numbers of the DNNND repeat and decreasing numbers of the DDNHNDN HNND repeat were associated with decreased quinine sensitivity. In contrast, in 83 freshly isolated strains from Africa, a significant association was not seen between quinine sensitivity and the number of DNNND repeats, and an increased number of DDNHNDNHNND repeats was associated with decreased quinine sensitivity (5) . Lastly, in 29 fresh isolates from Kenya, two DNNND repeats were associated with decreased sensitivity to quinine compared to the sensitivity of parasites with one or three copies, and there was no association between the number of DDNHNDNHNND repeats and quinine sensitivity (30) . Our study adds the analysis of a larger number of isolates from Africa. We found only a modest trend toward decreased quinine sensitivity in isolates with two copies of either repeat. We also offer the first consideration of pfnhe1 polymorphisms and clinical outcomes. The number of either repeat was not associated with response to quinine therapy. Our results add to uncertainty regarding the importance of pfnhe1 polymorphisms in mediating quinine sensitivity and treatment response. More broadly, our finding of only modest associations between pfmdr1 and pfnhe1 polymorphisms and quinine sensitivity and treatment response are consistent with the con- clusion that quinine sensitivity is a complex trait, with polymorphisms in multiple genes probably contributing to the phenotype (18, 28) . Simple molecular markers for resistance of malaria parasites to available drugs are valuable, as they allow the ready characterization of the sensitivity of parasites without the complex infrastructure required for clinical trials or in vitro analysis of parasites (36) . Such data can help to guide treatment policy. For quinine, our results and prior studies suggest contributions of polymorphisms in multiple genes to drug sensitivity, but no single mutation or set of polymorphisms has consistently been a robust marker for in vitro quinine sensitivity. Consistent with this result, we saw, at best, only modest associations between previously identified polymorphisms and in vitro quinine sensitivity or quinine treatment outcomes. Thus, at present, straightforward markers for the responsiveness of P. falciparum to quinine are not available. Our analysis was limited to known markers of interest, and it is likely that additional polymorphisms contribute to quinine sensitivity. Further studies, including whole-genome sequencing strategies, may be needed to better characterize the molecular basis of quinine sensitivity and allow a better appreciation of the extent to which alterations in quinine sensitivity are limiting the antimalarial efficacy of this important drug.
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